AIM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients

AIM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients

Antiangiogenic therapy, such as bevacizumab (BEV), has improved progression-free survival (PFS) and overall survival (OS) in high-risk patients with epithelial ovarian cancer (EOC) according to several clinical trials. Clinically, no reliable molecular biomarker is available to predict the treatment...

Full description

Bibliographic Details
Main Authors: Po-Chao Hsu, Tai-Kuang Chao, Yu-Ching Chou, Mu-Hsien Yu, Yu-Chi Wang, Yi-Hsin Lin, Yi-Liang Lee, Li-Chun Liu, Cheng-Chang Chang
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Journal of Clinical Medicine
Subjects:
epithelial ovarian cancer (EOC)
antiangiogenic therapy
bevacizumab
complement C3
C5
AIM2 inflammasome
Online Access:https://www.mdpi.com/2077-0383/10/19/4529

Internet

https://www.mdpi.com/2077-0383/10/19/4529

Similar Items